Health Canada approves drug for postpartum depression treatment

Health Canada has approved ZURZUVAE (zuranoline), the first drug specifically for treating moderate to severe postpartum depression, affecting one in five women in Canada. This 14-day treatment shows significant symptom improvement as early as day three, with patients experiencing an average reduction of 17.8 points on the Hamilton Rating Scale by day 15. While it offers hope for maternal mental health, side effects include dizziness and sedation, and safety during breastfeeding is uncertain. Biogen emphasizes the importance of addressing this critical unmet need for effective treatment in postpartum care.

Want More Context? 🔎